Compare Aurora Cannabis Inc (ACB) vs CAVA Group Inc (CAVA) Price & Performance

Aurora Cannabis (ACB) trades at $2.71, down 4.58% on the day, with a bearish technical outlook. The company reported a net income of $1.59 million in 2025, a significant improvement from a $69 million loss in 2024, though 2026 guidance projects a net loss of $136 million. Revenue grew to $343.29 million in 2025, but faces headwinds from Canadian reimbursement pressures. Analyst consensus is mixed, with 21.43% buy, 57.14% hold, and 21.43% sell ratings.

The stock's low P/B of 0.47 suggests undervaluation, but negative profitability metrics and a projected reset year in 2027 pose risks. Investment appeal hinges on execution in high-margin international medical markets, though volatility and competitive pressures remain key concerns for shareholders.

CAVA stock is trading at $71.91, down 6.46% with a bearish technical signal. The company shows strong revenue growth reaching $1.18 billion in 2025 with positive net income of $63.74 million, though valuation metrics remain elevated with a P/E of 138.29. Recent earnings beat expectations in Q1 2026 with $0.20 EPS versus $0.17 expected. Analyst sentiment remains strongly positive with 72% buy ratings and a $94.19 consensus price target, representing 31% upside potential from current levels.

The outlook remains favorable given CAVA's expansion trajectory and market share gains in the fast-casual segment, though high valuation multiples and margin pressures present risks. The stock's recent pullback offers potential entry point for growth investors, but requires monitoring of same-store sales trends and competitive dynamics in the restaurant industry.